Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was natural for the scientists to be hopeful when they tested the possibility of an Ozempic-like drug to improve Parkinson's disease symptoms, in a trial. However, the results were far from what they expected.
The new study has cast doubt on the potential of GLP-1 drugs, like Ozempic and Wegovy, to treat neurodegenerative diseases such as Parkinson’s.
